retatrutide phase 2 nejm 2023 weight loss percent 48 weeks First-in-Class 'Triple-G'! Retatrutide, a first-in-class GIP, GLP-1 & Glucagon triple hormone receptor agonist drug leads to nearly 29% in first pivotal test! Eli Lilly announced positive topline results from the Retatrutide Week by Week: Weight
Pay in 4 interest-free payments of $6.91 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27

























